• Je něco špatně v tomto záznamu ?

Isatuximab for the treatment of relapsed/refractory multiple myeloma

PG. Richardson, M. Beksaç, I. Špička, J. Mikhael

. 2020 ; 20 (12) : 1395-1404. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011791

INTRODUCTION: Although new drug classes have significantly extended survival of patients with multiple myeloma, they continue to experience multiple relapses and/or become refractory to treatment. Therefore, novel therapies and treatment combinations with different mechanisms of action are needed to improve the outcomes of patients with relapsed/refractory multiple myeloma. AREAS COVERED: Here, the authors review the published data regarding the development and clinical investigation of isatuximab, a CD38 monoclonal antibody, for treatment of patients with relapsed/refractory multiple myeloma. The mechanisms of action, clinical efficacy, and safety of isatuximab treatment are summarized. EXPERT OPINION: Isatuximab is approved in combination with pomalidomide/dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab displays a manageable safety profile, with infusion reactions being the most common adverse events. Isatuximab is currently being further evaluated in combination with other backbone regimens in relapsed/refractory and newly diagnosed multiple myeloma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011791
003      
CZ-PrNML
005      
20210507102221.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14712598.2021.1841747 $2 doi
035    __
$a (PubMed)33111607
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Richardson, Paul G $u Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute , Boston, MA, USA
245    10
$a Isatuximab for the treatment of relapsed/refractory multiple myeloma / $c PG. Richardson, M. Beksaç, I. Špička, J. Mikhael
520    9_
$a INTRODUCTION: Although new drug classes have significantly extended survival of patients with multiple myeloma, they continue to experience multiple relapses and/or become refractory to treatment. Therefore, novel therapies and treatment combinations with different mechanisms of action are needed to improve the outcomes of patients with relapsed/refractory multiple myeloma. AREAS COVERED: Here, the authors review the published data regarding the development and clinical investigation of isatuximab, a CD38 monoclonal antibody, for treatment of patients with relapsed/refractory multiple myeloma. The mechanisms of action, clinical efficacy, and safety of isatuximab treatment are summarized. EXPERT OPINION: Isatuximab is approved in combination with pomalidomide/dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab displays a manageable safety profile, with infusion reactions being the most common adverse events. Isatuximab is currently being further evaluated in combination with other backbone regimens in relapsed/refractory and newly diagnosed multiple myeloma.
650    _2
$a dospělí $7 D000328
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x terapeutické užití $7 D000077269
650    _2
$a mnohočetný myelom $x farmakoterapie $x patologie $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x patologie $7 D009364
650    _2
$a recidiva $7 D012008
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Beksaç, Meral $u Department of Hematology, School of Medicine, Ankara University , Ankara, Turkey
700    1_
$a Špička, Ivan $u 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital , Prague, Czech Republic
700    1_
$a Mikhael, Joseph $u Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center , Phoenix, AZ, USA
773    0_
$w MED00181398 $t Expert opinion on biological therapy $x 1744-7682 $g Roč. 20, č. 12 (2020), s. 1395-1404
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33111607 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507102221 $b ABA008
999    __
$a ok $b bmc $g 1650228 $s 1132170
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 12 $d 1395-1404 $e - $i 1744-7682 $m Expert opinion on biological therapy $n Expert Opin Biol Ther $x MED00181398
LZP    __
$a Pubmed-20210420
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace